Compare Bristol-Myers Squibb Co (BMY) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs VNET Group Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while VNET Group Inc trades at $7.79 (market cap $2.21B). The key difference: Bristol-Myers Squibb Co is far larger — about 52.6× VNET Group Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| BMY | VNET | |
|---|---|---|
Market Cap | $116.30B | $2.21B |
Sector | Health | Technology |
52-Week High | $62.37 | $14.03 |
52-Week Low | $42.60 | $7.34 |
Enterprise Value | $152.24B | $5.34B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
VNET Group trades at $7.72, down 3.62% on the day, with a bearish technical signal and negative earnings momentum after missing Q1 2026 EPS estimates. The company reported a net loss of $256.77 million in 2025, with profitability metrics like ROE at -43.21% indicating financial strain. However, revenue grew to $9.95 billion, and analyst sentiment remains largely positive with a 62.5% buy rating, citing AI-driven demand and new strategic investments from entities linked to CATL.
The outlook is mixed: strong revenue growth and strategic positioning in data centers offer upside, but persistent losses and high debt pose significant risks. Investors should weigh the potential from AI expansion against execution challenges and financial health concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
